Results you can trust
Introducing the first and only FDA-approved complementary test for PD-L1 expression associated with enhanced survival with OPDIVO® for non-squamous NSCLC.
Leading the way
in PD-L1 testing
Introducing the first and only FDA-approved test to assess patients with NSCLC for KEYTRUDA® (pembrolizumab).
Join a CAP Today and Dako webinar
Standards for IHC Controls:
with Clive Taylor, M.D., DPhil, FrcPath
Next Generation Cancer Profiling
Parallel DNA sequencing of cancer-associated targets.
Atlases of Stains
Read our Atlas of Stains (FLEX Ready-to-Use) and our Atlas of Special Stains.
Dako Product Catalog
Download the 2015 Pathology Product Catalog.
Free IHC Webinar
Standards for IHC Controls: Expert Recommendations by Clive R. Taylor.